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Inspired by biologically active natural products, a hybrid analogue that combines the N-Me urocanic side 
chain of the sarcodictyin family of compounds with the chalcone motif has been proposed, synthesised 
and examined for antiproliferative activity in three cancer cell lines and one normal primary cell line. The 
analogues are all synthesised in one or two steps from commercially available materials and, of the 
compounds examined, the proposed hybrid analogue displays the most active and selective inhibition of 10 
cell proliferation in human colon cancer cell line HT29 (IC50 2.9 µM) and highly metastatic human breast 
carcinoma MDA-MB-231 (IC50 4.8 µM). 
Introduction 
Eleutherobin 11,2 and the structurally related sarcodictyin family 
of compounds 23,4 are natural products originally isolated from 15 
soft coral. They possess potent anti-tumour activity with a 
mechanism of action similar to paclitaxel (Taxol®) through the 
stabilisation of microtubules.5-8 They have attracted great interest 
as they display nanomolar cytotoxicity against a range of cancer 
cell lines including Taxol®-resistant cell lines5,9,10 (Fig. 1). 20 
 Fig. 1 Eleutherobin 1 and sarcodictyin A (2a) and B (2b) 
 
 Owing to their limited availability from corals, chemical 
synthesis is required to explore potential clinical application. The 25 
total syntheses of eleutherobin 111-14 and sarcodictyins A (2a) and 
B (2b)8,15-17 have been reported. Extensive structure-activity 
relationships of the sarcodictyins were conducted and found that 
the α,β unsaturated urocanic ester side chain was vital for 
biological activity.8,17,18 Removal of this pharmacophore resulted 30 
in complete loss of cytotoxicity and even subtle substitutions of 
the imidazole ring were not tolerated and resulted in decreased 
activity.  
 Gennari has reported the synthesis of a variety of simplified 
eleutherobin analogues, using enantioselective allyltitanation 35 
reactions and ring closing metathesis (RCM) as key-steps,19-23 
culminating in the formal synthesis of eleutherobin.24,25 The 
simplified analogues, exemplified by compounds 3 and 4, 
retained potent microtubule-stabilising properties (ED90 effective 
dose that induces 90% tubulin polymerisation) but exhibited 40 
reduced inhibition of tumour cell proliferation (IC50 concentration 
inhibiting cell proliferation by 50%) (Fig. 2). It was suggested 
that this may be the result of hydrolytic cleavage of the N-
methylurocanic ester due to a lack of substitution at C7, resulting 
in diminished activities, as the natural products are fully 45 
substituted at the equivalent position.23 Although most studies 
show that the ester is essential to biological activity, 8,17,18 Holmes 
reported simplified eleutherobin analogues 5 and 6 which 
displayed improved tubulin binding activities when the N-
methylurocanic ester side chain was absent.26 50 
Fig. 2 Gennari21,23 and Holmes26 simplified analogues. 
 Since the urocanic ester is required for potency in the natural 
products and can be susceptible to hydrolysis in simplified 
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Fig. 3 Rationale for urocanic-chalcone hybrid. 
analogues, we considered using ketone isosteres. Substituting the 
tricyclic core of the sarcodictyins with an aromatic group would 
generate compounds closely related to the structure of chalcones 5 
7 that are biologically active compounds themselves.27 We 
therefore proposed to investigate chalcone derivatives that feature 
the N-methylurocanic moiety, such as hybrid 8 shown in Fig. 3. 
 Despite the wealth of research in the area of chalcones and 
related compounds, very few examples have been reported which 10 
possess the framework of the proposed hybrid compound 8. 
These include compound 8a (R = H) generated as an intermediate 
in the synthesis of -lactam alkaloids.28 The structurally similar 
compound 9 in which the enone is conformationally constrained 
has been previously reported and exhibits potent and selective 15 
inhibition of P450 aromatase (P450 arom, CYP19), with possible 
theraputic applications in various hormone-dependent cancers, 
such as breast, prostate and uterine (Fig. 4).29-33 Similar 
compounds have also been investigated as agonists of the 2B and 
2C adrenergic receptors for the treatment of chronic pain.
34,35 20 
 The chalcone motif is a privileged structure present in an 
extensive range of biologically active molecules that display anti-
inflammatory, anti-infective, anti-oxidative, anti-malarial and 
anti-cancer activities.27,36 Recent reports have shown chalcones 
having a trimethoxyphenyl group exhibit potent biological 25 
activities against various cancer cell lines, selected examples of 
which are shown by compounds 10,37 1138 and 1239 in Fig. 4. The 
trimethoxyphenyl group is also present in a range of biologically 
active compounds such as colchicine 13,40 combretastatin A4 
1441 and podophyllotoxin 15,42,43 all of which also bind to tubulin 30 
but induce depolymerisation (Fig. 4). 
 Colchicine 13 and podophyllotoxin 15 display limited clinical 
potential due to severe toxicity; however, the phosphate prodrug 
of combretastatin (CA4P) is a promising lead compound under 
clinical evaluation.40,41,44 The success of combretastatin 14 35 
demonstrates that structural complexity is not necessary for 
potent biological activity and that simple molecular scaffolds can 
provide new lead compounds. One emerging strategy in the 
development of new drugs involves combining key 
pharmacophores from existing natural products to generate novel 40 
chimeric compounds with improved biological properties.45-49 
 
Fig. 4 Examples of biologically active arylmethylethers  
 Combining the pharmacophores of the trimethoxyaryl motif 
and the urocanic ester side chain, the synthesis and 45 
antiproliferative activity of various urocanic-chalcone hybrid 
derivatives is now described. 
Results and discussion 
Chemical Synthesis 
The chalcone hybrid derivatives were obtained by a Claisen-50 
Schmidt condensation between the methoxy-substituted 
acetophenones A, B and/or C and the heteroarylcarboxaldehyde 
1,2,3,4 and 6-CHO (Scheme 1). N-Me imidazole derivatives C5 
and C7 were obtained by methylation of the corresponding N-H 
imidazole, compounds C3 and C6 respectively. 55 
 
Scheme 1 Synthesis of proposed urocanic-chalcone hybrid derivatives. 
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Table 1 Synthesis and inhibition of cell proliferation of various hybrid analogues 
 
Entry Compound R1 R2 R3 R4 Methoda Yield (%) 
IC50 (µM
 )b 
HT29 MDA-MB-231  LNCaP FEK-4 
1 A1 H OMe H H i 43 > 500 > 500 > 500 > 500 
2 B1 OMe OMe H H i 53 86.0 ± 3.2 102.4 ± 3.7 104.6 ± 9.8 135.1 ± 37.2 
3 C1 OMe OMe OMe H i 74 43.0 ± 8.0 49.9 ± 11.7 59.9 ± 9.2 156.1 ± 37.7 
4 A2 H OMe H Me ii 63 61.8 ± 2.9 53.5 ± 5.7 75.5 ± 6.5 188.2 ± 91.8 
5 B2 OMe OMe H Me ii 79 60.4 ± 13.1 42.8 ± 11.1 56.3 ±12.4 161.7 ± 48.2 
6 C2 OMe OMe OMe Me ii 83 12.5 ± 4.8 18.0 ± 7.7 69.5 ± 11.0 117.5 ± 24.6 
7 A3 H OMe H H iii 53 23.6 ± 4.9 17.6 ± 4.7 33.5 ± 9.6 87.1 ± 14.1c 
8 B3 OMe OMe H H iii 74 37.9 ± 10.5 18.2 ±2.1 46.2 ± 6.7 84.2 ± 19.0 
9 C3 OMe OMe OMe H iii 74 19.5 ± 0.6 22.9 ± 3.7 48.1 ± 7.6 53.2 ± 7.4 
10 C3-H2 OMe OMe OMe H iv 57 > 500 223.4 ± 20.6 367.7 ± 141.8 > 500
d 
11 C4 OMe OMe OMe Me iii 54 15.9 ± 1.9 16.9 ± 1.5 30.6 ± 8.4 49.9 ± 1.9 
12 C5 OMe OMe OMe Me v 36 2.9 ± 1.2 4.8 ± 2.3 48.4 ± 13.5 85.0 ±25.9 
13 C6 OMe OMe OMe H iii 38 5.0 ± 0.5 4.9 ± 0.9 17.1 ± 3.4 28.6 ± 10.7 
14 C7 OMe OMe OMe Me vi 54 4.2 ± 0.6 4.9 ± 0.2 11.0 ± 3.6 17.5 ± 2.3 
15e 3 - - - - - - 5f n.d n.d n.d 
16g Doxorubicin - - - - - - 0.164d 0.120d 0.154d n.d 
a Methods (i) 1 equiv. LiOH.H2O, (ii) NaOH, grinding, (iii) 2 equiv. BF3.OEt2, (iv) H2, Pd/C, (v) NaH, MeI, DMF and (vi) Cs2CO3, MeI. 
b IC50 is the 
concentration that inhibits 50% cell proliferation. Values are the mean from three independent experiments, except c two and d one experiment, with 
quadruplicate readings in each. e Reference 21, f paclitaxel IC50<5nM. 
g Doxorubicin was used as a positive control. n.d not determined.5 
 LiOH.H2O has been reported to catalyse the Claisen-Schmidt 
reaction of various aryl methyl ketones with heteroaryl aldehydes 
under mild conditions.50 The reactions of 2-
pyrrolecarboxaldehyde 1-CHO with acetophenones A, B and C 
using 10 mol% of LiOH.H2O, as described, were unsuccessful, 10 
although using 1 equivalent gave the products A1, B1 and C1 in 
moderate yields (Method (i), entries 1-3, Table 1). Following 
recently reported solvent-free conditions,51 grinding 1-methyl-2-
pyrrolecarboxaldehyde 2-CHO with acetophenones A, B and C 
in the presence of NaOH with a mortar and pestle gave the 15 
corresponding products A2, B2 and C2 after only 5 min. in 
moderate to good yields (Method (ii), entries 4-6, Table 1). 
Unfortunately, attempts to apply this method to other substrates 
failed.  
 The imidazole derivatives gave variable results under these 20 
conditions and treatment with 50 mol% of BF3.OEt2, as described 
by Narender,52 only gave starting materials, presumably because 
of unproductive co-ordination to the basic nitrogen in imidazole. 
Use of two equivalents of BF3.OEt2, followed by decomplexation 
with NaOH, gave the desired urocanic-chalcone derivatives A3, 25 
B3 and C3 in moderate to good yields (Method (iii), entries 7-9, 
Table 1). 
 To examine the effect of the enone double bond, the dihydro-
derivative C3-H2 was obtained in 57% yield by hydrogenation of 
the conjugated double bond of compound C3 under standard 30 
conditions (entry 10, Table 1). Having obtained the core 
framework of the urocanic-chalcone hybrid with acetophenones 
A, B and C, further derivatives were focused on the 
trimethoxyaryl motif C. 1-Methylimidazole-2-carboxaldehyde 4-
CHO is commercially available and gave the non-natural 35 
urocanic-chalcone 1-Me derivative C4 in the presence of 
BF3.OEt2 in 54% yield (entry 11). Methylation of the imidazole 
group present in C3 using Cs2CO3 and MeI gave a 50:50 ratio of 
1-Me C4 and 3-Me C5 isomers, which proved difficult to 
separate. Using the conditions reported for the selective 40 
methylation of the N-urocanic methyl ester,53 NaH and MeI in 
DMF at 0 °C selectively gave the desired 3-Me isomer C5 in a 
75:25 ratio of C5:C4 that could be separated by silica gel column 
chromatography (entry 12). The 2-substituted imidazole 
derivative C6 was obtained using excess BF3.OEt2 and was 45 
methylated under standard conditions to afford compound C7 
without the formation of isomers due to the symmetry of the 
imidazole substituent (entries 13 and 14). 
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Cell Proliferation Assays 
In all cases, the only stereoisomer observed was the 
thermodynamic trans-product, identified by a characteristic 3J 
coupling of ca. 15 Hz. All compounds were determined to be ≥ 
95% pure by HPLC and were examined for inhibition of cell 5 
proliferation in vitro using the MTS assay54 with various cell 
lines and the results are reported as the concentration required to 
inhibit 50% cell proliferation (IC50) (Table 1). The results are the 
mean of three experiments, except where indictated in Table 1, 
and were performed on different days with different batches of 10 
cells. Three cancer cell lines were investigated, human colon 
carcinoma HT29, highly metastatic human breast carcinoma 
MDA-MB-231 and an androgen-dependent human prostate 
carcinoma LNCaP. In addition, a normal primary cell line, human 
skin fibroblasts FEK-4, were also investigated in the MTS assay 15 
to examine selectivity.  
 The addition of methoxy substituents significantly increased 
activity of the N-H pyrrole derivatives (A1-C1) and was also 
observed to a lesser extent with N-Me pyrrole hybrids (A2-C2) 
(entries 1-3 and 4-6, Table 1). The effect of the substituents was 20 
not evident with N-H 4-imidazole derivatives (A3-C3), which 
showed moderate levels of activity against all three cancer cell 
lines, but without much selectivity (entries 7-9). The importance 
of the enone was demonstrated by the dramatic loss of activity of 
the saturated derivative C3-H2 (entry 10). The non-natural 25 
methylated analogue C4 gave similar levels of activity to the 
unsubstituted compound C3, although the proposed N-
methylurocanic trimethoxy chalcone hybrid C5, which has the 
side chain present in the sarcodictyins, did exhibit enhanced 
antiproliferative activity and selectivity, especially with HT29 30 
and MDA-MB-231 (entries 11 and 12). Interestingly, the 
symmetrical N-H 2-imidazole hybrid C6 and the methylated 
derivative C7 showed similar levels of potency as hybrid C5 
against HT29 and MDA-MB-231 and displayed improved 
activity against LNCaP, although they are much less selective and 35 
also inhibited cell proliferation in the normal primary human skin 
fibroblasts FEK-4 (entries 13 and 14).  
Conclusions 
Combining pharmacophores present in the sarcodictyin and 
chalcone family of compounds, the hybrid analogue 8 was 40 
proposed and synthesised together with related isomers. It is of 
interest that both sarcodictyin and chalcones interact with tubulin, 
although they have opposing effects on microtubule assembly. 
From our investigations however, the lead compound is indeed 
hybrid chalcone C5 which includes the N-methylurocanic side 45 
chain present in the sarcodictyins. It is the most active and most 
selective compound in the series investigated, displaying 
selective antiproliferative activity against HT29 and MDA-MB-
231 cell lines.  
 It is worthy of note that the urocanic-chalcone derivative C5 50 
can be obtained in only two synthetic steps and displays similar 
levels of antiproliferative activity against HT29 as the simplified 
eleutherobin analogue 3 previously reported21 (Fig. 2 and Table 
1, entry 15). Owing to their ease of synthesis, low molecular 
weight and promising initial results, these hybrid compounds 55 
could be used in a fragment-based lead discovery (FBLD) 
approach to achieve more potent compounds. 
 Hybrid C5, together with others examined in this series, will 
be further investigated to determine the biological mode of action 
and will be reported in due course.  60 
 The simple chalcone scaffold combined with the N-
methylurocanic ester side chain present in the sarcodictyin family 
of compounds has afforded biologically active hybrid analogues 
with the potential for improved biological activities and drug-like 
properties due to their ease of synthesis and the diverse range of 65 
inexpensive and commercially available starting materials. 
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